Cooper Companies (COO) Q3 2025: MyDay Fitting Sets Surge 50%, Positioning for Daily SiHy Share Rebound
Cooper Companies’ third quarter revealed a decisive pivot toward premium daily lenses as MyDay fitting sets rose over 50% year-over-year, signaling a structural shift in the contact lens portfolio but pressuring near-term revenue as clarity volumes declined sharply. Management is prioritizing sustainable margin expansion and free cash flow, leveraging recent IT and integration investments to unlock further organizational efficiency into 2026. Guidance remains cautious for Q4, but the groundwork for a return to market-level growth is being laid through contract wins, new launches, and a reset in channel inventory dynamics.
Summary
- MyDay Expansion Drives Portfolio Reset: Fitting set activity and private label wins establish a new growth foundation for daily silicone hydrogel.
- Margin Focus Amid Top-Line Volatility: Cost discipline and CapEx normalization support robust free cash flow, even as regional demand remains uneven.
- 2026 Setup Hinges on Execution: Organizational restructuring and product launches will determine if COO regains share above market pace.
Performance Analysis
Cooper Companies delivered 5.7% reported revenue growth and 2% organic growth in Q3, with consolidated revenues at $1.06 billion. Gross margin improved by 70 basis points to 67.3%, aided by efficiency gains, product mix, and FX tailwinds. Operating margin expanded to 26.1%, reflecting disciplined SG&A management and a double-digit increase in R&D investment, as both CooperVision (CVI) and CooperSurgical (CSI) advanced development pipelines and regulatory initiatives. Free cash flow was strong at $165 million, supporting $52 million in share repurchases, while net leverage improved to 1.77x.
Segment dynamics were mixed: CVI revenues of $718 million (6.3% reported, 2.4% organic) were pressured by a rapid shift from clarity to MyDay, especially in Asia-Pac, where e-commerce channels saw double-digit declines. EMEA outperformed, becoming CVI’s largest region, with 14% reported and 6% organic growth. CSI posted $342 million in sales (4.5% reported, 2% organic), with fertility up 6% (3% organic) on EMEA genomics gains, but ongoing softness in Asia-Pac cycles and delayed capital purchases.
- Daily SiHy Mix Shift: MyDay fitting sets and trial lenses surged, but clarity volumes dropped, delaying revenue conversion and creating near-term headwinds.
- Asia-Pac Volatility: Pure play e-commerce and channel inventory reductions in China and Japan weighed on both volume and mix, with minimal margin impact due to low profitability in these channels.
- CapEx Cycle Peaks: Large MyDay-related investments are winding down, paving the way for higher free cash flow conversion in coming years.
Despite short-term sales softness, the company’s margin profile and cash generation remain resilient, underpinned by an explicit focus on operational leverage and product mix optimization.
Executive Commentary
"We have over 30 brand new MyDay private label contracts and launches going on right now. We have almost 50% increase in our fitting sets that are out in the market year over year right now. And we have over 300% increase in trial sets, trial lenses associated with those fitting sets. I mean, those are, they're pretty dramatic numbers out there that support the fact that we're going to do well with MyDay and we're going to get MyDay going again."
Al White, President and CEO
"CapEx is going to come down on a percentage basis and on an absolute dollar basis...the peak level of CapEx that we've been seeing, it's not going to be normalizing. And that's what drives, along with the other steps that we're taking, will drive the free cash flow higher."
Brian Andrews, Chief Financial Officer
Strategic Positioning
1. MyDay as the Flagship Growth Lever
MyDay, premium daily silicone hydrogel (SiHy) lens, is now the centerpiece of COO’s growth strategy. Manufacturing constraints have been resolved, enabling a global rollout of fitting sets and trial lenses, which have increased over 50% year-over-year. The company secured more than 30 new private label contracts, and MyDay Multifocal and Toric launches are expanding into new geographies. Management expects these investments to drive a step-change in revenue conversion, although the lag between fitting activity and sales recognition is creating near-term turbulence.
2. Portfolio Realignment and Channel Reset
Clarity, value-priced daily SiHy lens, saw demand erode as practitioners and accounts in Asia-Pac and select markets prioritized MyDay fittings. This dynamic was particularly acute in markets where the two products lacked clear differentiation. COO is now repositioning Clarity for success in lower-priced, high-volume channels and focusing MyDay in premium segments, aiming to restore balanced growth as fitting activity converts to revenue.
3. Margin and Cash Flow Optimization
Operating margin expansion and free cash flow are top priorities, with CapEx normalization following the MyDay capacity build-out. Tariff mitigation efforts are expected to reduce headwinds to approximately $24 million in 2026, and ongoing SG&A discipline will offset gross margin pressure from product mix and tariffs. COO targets $2 billion in free cash flow over the next three years, driven by improved working capital and efficiency initiatives.
4. Organizational Restructuring and Integration
Management is undertaking a fresh review of the entire organizational structure, following years of acquisitions and recent IT upgrades. This restructuring targets G&A efficiency, leveraging automation and digital tools to support scalable growth. The company is evaluating potential charges and P&L benefits, with more details expected next quarter.
5. Fertility and Surgical Steady Amid Cyclical Headwinds
CSI’s fertility business, while pressured by delayed capital spending and Asia-Pac cycle softness, remains a long-term growth opportunity. Underlying demand is supported by demographic trends and rising access to treatment. The office and surgical portfolio is seeing double-digit growth in labor and delivery products, offsetting Paragard volume declines with price increases.
Key Considerations
This quarter marks a strategic inflection for COO, as the company shifts from a legacy volume-driven model to a premium, margin-focused portfolio anchored by MyDay. Execution risk remains as fitting set momentum must translate into sustainable revenue and market share gains.
Key Considerations:
- Fitting Set Conversion Timeline: The lag between MyDay fitting activity and revenue recognition introduces forecasting complexity and near-term volatility.
- Asia-Pac Channel Volatility: E-commerce and regional price competition are ongoing headwinds, but contribute little to consolidated margin.
- Clarity Repositioning: Success depends on restoring volume in targeted value channels without cannibalizing MyDay’s premium positioning.
- Restructuring Execution: Realizing cost savings from integration and IT upgrades will be critical to offsetting gross margin pressures.
- Fertility Market Recovery Pace: The rebound in Asia-Pac cycles and clinic investment is a key variable for CSI’s growth trajectory.
Risks
Key risks include: slower-than-expected conversion of MyDay fitting activity to revenue, persistent channel inventory reductions, and competitive pricing in Asia-Pac diluting market share. Tariff pressures, while mitigated, remain a drag on gross margin. Fertility’s recovery is contingent on macro and clinic investment cycles, while organizational restructuring may bring transitional disruption or unforeseen charges.
Forward Outlook
For Q4, Cooper Companies guided to:
- Consolidated revenue of $1.049 to $1.069 billion (2% to 4% organic growth)
- CooperVision revenue of $700 to $713 million (2% to 4% organic)
- CooperSurgical revenue of $350 to $356 million (2% to 4% organic)
- Non-GAAP EPS of $1.10 to $1.14
- Free cash flow of ~$100 million for Q4, ~$385 million for FY25
For full-year 2026, management expects:
- Market-level or better CVI growth, led by MyDay and MySite launches
- Operating margin expansion and $2 billion free cash flow over three years
Leadership emphasized a conservative stance in Q4 guidance, reflecting the lag in revenue conversion and ongoing channel risks.
- MyDay fitting activity and contract wins are expected to drive a return to market growth in 2026
- Tariff mitigation and restructuring should support operating leverage and cash flow
Takeaways
Cooper Companies is in the midst of a strategic portfolio reset, with MyDay emerging as the critical growth engine, but near-term revenue visibility remains clouded by fitting set conversion lags and regional channel disruption.
- Daily SiHy Shift: MyDay’s premium positioning and contract wins are laying the foundation for share recovery, but clarity’s rapid decline exposes the revenue model to timing risk.
- Margin and Cash Flow Discipline: CapEx normalization and cost management are supporting robust free cash flow, even as gross margin faces product mix and tariff headwinds.
- Execution Watchpoint: The pace at which fitting activity converts to revenue, and the ability to reposition clarity, will determine if COO can outpace the market in 2026.
Conclusion
Cooper Companies is navigating a complex transition as it pivots to a premium lens portfolio, with MyDay fitting set momentum and new contracts signaling a potential inflection in growth. Sustained margin discipline and successful restructuring will be essential to translating this activity into market share gains and long-term value creation.
Industry Read-Through
The pronounced shift from value to premium daily SiHy lenses, as seen in COO’s MyDay surge and clarity decline, highlights a broader industry trend toward premiumization and channel segmentation. The volatility in Asia-Pac e-commerce and the lag between fitting activity and revenue recognition are likely to echo across other lens manufacturers. Fertility’s gradual rebound in EMEA, despite persistent Asia-Pac softness, suggests that demographic and reimbursement tailwinds remain intact, though recovery will be uneven. Margin management and capital allocation discipline are increasingly critical as the sector faces both cyclical and structural headwinds.